Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 18 other studies
4,401people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
canagliflozin
placebo
Lowered renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes−34%
Reduced cardiovascular death, myocardial infarction, or stroke−20%
Lowered hospitalization for heart failure−39%
randomisedthe abstract, start to end
… causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; …
… infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P = 0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; …
← favours treatmentfavours comparator →
could be chanceRenal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causescanagliflozin vs placebo
HR 0.660.53–0.81
End-stage kidney diseasecanagliflozin vs placebo
HR 0.680.54–0.86
Cardiovascular death, myocardial infarction, or strokecanagliflozin vs placebo
HR 0.800.67–0.95
Hospitalization for heart failurecanagliflozin vs placebo
HR 0.610.47–0.80
SGLT2 inhibitorsCardiovascular eventsKidney outcomes
SGLT2 inhibitors × cardiovascular eventshelps?mixed
unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
1 / 7